OverviewSuggest Edit

Geron is a clinical-stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Imetelstat is designed to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.

TypePublic
Founded1990
HQMenlo Park, US
Websitegeron.com
Employee Ratings2.8

Latest Updates

Employees (est.) (Feb 2019)15
Revenue (FY, 2017)$1.1 M(-82%)
Share Price (Mar 2019)$1.6 (-1%)

Key People/Management at Geron

John A. Scarlett

John A. Scarlett

Chairman of the Board, President and Chief Executive Officer
Olivia K. Bloom

Olivia K. Bloom

Executive Vice President, Finance, Chief Financial Officer and Treasurer
Melissa A. Kelly Behrs

Melissa A. Kelly Behrs

Executive Vice President and Chief Business Officer
Andrew J. Grethlein

Andrew J. Grethlein

Executive Vice President and Chief Operating Officer
Aleksandra Rizo

Aleksandra Rizo

Executive Vice President and Chief Medical Officer
Stephen N. Rosenfield

Stephen N. Rosenfield

Executive Vice President, Chief Legal Officer and Corporate Secretary
Show more

Geron Office Locations

Geron has offices in Menlo Park and Canton
Menlo Park, US (HQ)
149 Commonwealth Dr
Canton, US
250 Royall St
Show all (2)
Report incorrect company information

Geron Financials and Metrics

Geron Revenue

Geron's revenue was reported to be $1.07 m in FY, 2017
USD

Net income (FY, 2018)

(27.0m)

EBIT (FY, 2018)

(31.1m)

Market capitalization (18-Mar-2019)

305.7m

Closing stock price (18-Mar-2019)

1.6

Cash (31-Dec-2018)

10.6m
Geron's current market capitalization is $305.7 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

1.3m36.4m6.2m1.1m

General and administrative expense

15.6m17.8m18.8m19.3m18.7m

R&D expense

23.2m17.8m18.0m11.0m13.4m

Operating expense total

40.2m36.9m36.8m30.3m32.1m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

35.4m5.1m

General and administrative expense

3.5m4.0m3.9m4.1m4.0m4.3m4.8m4.5m4.7m4.7m4.4m4.8m5.3m4.2m

R&D expense

5.3m5.2m5.2m6.0m4.8m4.1m5.0m4.6m4.3m3.4m2.5m2.6m2.4m3.2m

Operating expense total

8.9m9.2m9.0m10.1m8.8m8.3m9.8m9.1m9.0m8.0m6.9m7.4m7.8m7.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

13.0m42.8m21.2m12.8m16.3m10.6m

Accounts Receivable

1.1m

Inventories

Current Assets

67.1m153.4m115.9m116.1m96.0m166.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(38.4m)(35.7m)46.0k(29.5m)(27.9m)(27.0m)

Depreciation and Amortization

320.0k47.0k56.0k81.0k76.0k59.0k

Inventories

Accounts Payable

(2.0m)(364.0k)(873.0k)65.0k278.0k479.0k
Quarterly
USDQ3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(29.1m)(9.4m)27.2m(8.8m)(8.6m)(3.6m)(7.2m)

Depreciation and Amortization

357.0k

Accounts Payable

1.2m2.4m1.2m957.0k574.0k396.0k235.0k271.0k308.0k

Cash From Operating Activities

(29.9m)
USDY, 2018

Financial Leverage

1 x
Show all financial metrics
Report incorrect company information

Geron News and Updates

Geron Corporation Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Events

Conference Call Scheduled for 4:30 p.m. ET today Conference Call Scheduled for 4:30 p.m. ET today

Geron Announces Expansion of Leadership Team with Appointment of Chief Medical Officer

MENLO PARK, Calif., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced an expansion of its leadership team with the appointment of a new chief medical officer to support the Company’s clinical drug development efforts in hematology-oncology.

Geron Announces New Board Leadership Structure

CEO John A. Scarlett Appointed Chairman

Geron Reports Updated Results from Phase 2 Portion of IMerge at the 60th American Society of Hematology Annual Meeting

Data Support Initiation of Part 2, the Phase 3 portion of IMerge Data Support Initiation of Part 2, the Phase 3 portion of IMerge
Show more
Report incorrect company information

Geron Frequently Asked Questions

  • When was Geron founded?

    Geron was founded in 1990.

  • Who are Geron key executives?

    Geron's key executives are John A. Scarlett, Olivia K. Bloom and Melissa A. Kelly Behrs.

  • How many employees does Geron have?

    Geron has 15 employees.

  • Who are Geron competitors?

    Competitors of Geron include Heat Biologics, Cleveland BioLabs and Immune Design.

  • Where is Geron headquarters?

    Geron headquarters is located at 149 Commonwealth Dr, Menlo Park.

  • Where are Geron offices?

    Geron has offices in Menlo Park and Canton.

  • How many offices does Geron have?

    Geron has 2 offices.